Skip to main content

Table 2 Factors associated with the presence of at least one immune-associated escape mutation by fitting a uni-multivariable logistic regression model

From: Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Variables

Univariate analysisb

Multivariate analysisb

crude OR [95% CI]

p-value

adjusted OR [95% CI]

p-value

Gender (Female vs. Malea)

1.16 (0.76–1.78)

0.483

1.20 (0.77–1.87)

0.432

Age (per 1 year increase)

1.02 (1.00–1.03)

0.010

1.02 (1.00–1.03)

0.013

HBV-DNA (per 1 log10 IU/ml increase)

1.03 (0.94–1.14)

0.490

1.10 (0.99–1.23)

0.079

LAM

1.16 (0.65–2.08)

0.616

1.46 (0.71–3.02)

0.307

ADV

1.44 (0.96–2.17)

0.078

1.31 (0.83–2.06)

0.250

ETVc

1.28 (0.71–2.31)

0.409

2.04 (0.97–4.29)

0.060

TDF

0.76 (0.31–1.87)

0.547

1.13 (0.43–3.02)

0.803

Geographical origin

 Southa

1

 

1

 

 West

0.71 (0.43–1.17)

0.175

1.03 (0.55–1.89)

0.937

 North

0.55 (0.18–1.62)

0.276

0.72 (0.23–2.28)

0.581

 East

0.75 (0.46–1.22)

0.250

1.26 (0.62–2.55)

0.519

Year of collection

 1997-2002a

1

 

1

 

 2003–2005

1.07 (0.42–2.71)

0.892

0.79 (0.28–2.20)

0.651

 2006–2008

2.37 (1.11–5.07)

0.026

1.65 (0.67–4.01)

0.273

 2009–2012

1.79 (0.84–3.83)

0.134

1.36 (0.50–3.68)

0.547

Genotype (D vs. Aa)

2.19 (1.43–3.34)

< 0.0001

2.20 (1.32–3.67)

0.002

  1. a Reference group
  2. b The analysis was led on 650 patients for whom type of anti-HBV drugs received was known
  3. c Among 64 ETV-treated patients, 26 received LMV
  4. P-value in italic are statistically significant
  5. Abbreviations: ADV adefovir, CI Confidence interval, ETV entecavir, LAM lamivudine, OR Odd ratio, TDF tenofovir